teclistamab Tecvayli
Selected indexed studies
- Teclistamab: First Approval. (Drugs, 2022) [PMID:36352205]
- ** (, 2024) [PMID:38917260]
- ** (, 2024) [PMID:39466931]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Teclistamab: Mechanism of action, clinical, and translational science. (2024) pubmed
- Teclistamab. (2006) pubmed
- Teclistamab: First Approval. (2022) pubmed
- Linvoseltamab (Lynozyfic) for multiple myeloma. (2025) pubmed
- Antibodies to watch in 2023. (2023) pubmed
- PMID:38917260 (2024) pubmed
- PMID:39466931 (2024) pubmed
- Teclistamab-cqyv (Tecvayli) for multiple myeloma. (2022) pubmed
- FDA Approval Summary: Teclistamab-A Bispecific CD3 T-Cell Engager for Patients with Relapsed or Refractory Multiple Myeloma. (2024) pubmed
- Teclistamab for relapsed or refractory multiple myeloma. (2025) pubmed